Scientific Reports (Oct 2022)

Long-term hospitalisations in survivors of paediatric solid tumours in France

  • Daniel Bejarano-Quisoboni,
  • Nathalie Pelletier-Fleury,
  • Rodrigue S. Allodji,
  • Brice Fresneau,
  • Majorie Boussac,
  • Hélène Pacquement,
  • François Doz,
  • Delphine Berchery,
  • Claire Pluchart,
  • Piere-Yves Bondiau,
  • Julie Nys,
  • Angela Jackson,
  • Charlotte Demoor-Goldschmidt,
  • Agnes Dumas,
  • Cécile Thomas-Teinturier,
  • Boris Schwartz,
  • Neige Journy,
  • Carole Rubino,
  • Giao Vu-Bezin,
  • Dominique Valteau-Couanet,
  • Chiraz El-Fayech,
  • Christelle Dufour,
  • Nadia Haddy,
  • Florent de Vathaire

DOI
https://doi.org/10.1038/s41598-022-22689-w
Journal volume & issue
Vol. 12, no. 1
pp. 1 – 10

Abstract

Read online

Abstract The late effects of treatments for childhood cancers may lead to severe and multiple health conditions requiring hospitalisation. We aimed to estimate the hospitalisation rate among childhood cancer survivors (CCS) in France, to compare them with the general population and to investigate the associated factors. We matched total of 5439 5-year solid CCS diagnosed before the age of 21 between 1945 and 2000 by sex, birth year and region of residence to 386,073 individuals of the French general population. After linkage with the national hospital discharge database, we estimated the relative hospitalisation rate (RHR), the absolute excess risks (AERs) and the relative bed-day ratio (RBDR) during 2006–2018. We used generalised linear models to estimate associations between hospitalisation and survivor characteristics. Overall, the RHR was 2.49 (95% confidence interval [CI] 2.46–2.52) and the RBDR was 3.49 (95% CI 3.46–3.51). We found that neoplasm-related hospitalisations had the highest AER (105.8 per 1000 person-years), followed by genitourinary system diseases (34.4 per 1000 person-years) and cardiovascular diseases (19.2 per 1000 person-years). In adjusted analysis, CCS treated with chemotherapy (risk ratio [RR] 1.62, 95% CI 1.53–1.70), radiotherapy (RR 2.11, 95% CI 1.99–2.24) or both (RR 2.59, 95% CI 2.46–2.73) had a higher risk of hospitalisation than the ones who had not received any of these treatments. CCS treated during the past decades by chemotherapy and/or radiotherapy now had a higher hospitalisation risk for all main categories of diagnosis than the general population. Prevention strategies and medical surveillance programmes may promote a long-term decrease in the hospitalisation rate among CSS.